Reports from Department of Cardiovascular Medicine Provide New Insights into Heart Failure (Dapagliflozin and Right Ventricular-pulmonary Vascular Interaction In Heart Failure With Preserved Ejection Fraction: a Secondary Analysis of a...).

A study conducted by the Department of Cardiovascular Medicine in Rochester, Minnesota, explored the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on patients with heart failure with preserved ejection fraction (HFpEF). The study found that treatment with dapagliflozin for 24 weeks improved pulmonary vascular load and enhanced dynamic right ventricular-pulmonary vascular interaction during exercise in patients with HFpEF. These findings suggest that the benefits of SGLT2 inhibitors in HFpEF may be partially attributed to their effects on right ventricular-pulmonary vascular coupling. The study was funded by AstraZeneca, the National Institutes of Health (NIH), and the United States Department of Defense. [Extracted from the article]